#USA #New York #Securities Fraud #Pomerantz LLP #Larimar Therapeutics

Pomerantz Law Firm's Investigation on Larimar Therapeutics

In a recent move, the Pomerantz Law Firm has initiated an investigation concerning possible claims for investors involved with Larimar Therapeutics, Inc. (NASDAQ: LRMR). The investigation aims to uncover whether there have been any unlawful activities related to securities fraud involving Larimar and its key executives.

The focus of the investigation stems from significant announcements made by the company regarding their ongoing clinical trials for treating Friedreich's Ataxia with a drug named nomlabofusp. On September 29, 2025, Larimar indicated in a press release that they had encouraging data from a long-term study involving daily subcutaneous injections of the drug. However, the company also disclosed concerning safety issues, as seven participants experienced severe allergic reactions known as anaphylaxis during the trial. This revelation significantly impacted investor confidence, leading to a staggering decline of 33.66% in Larimar's stock, which dropped by $1.72 per share to close at just $3.38 the same day.

Just last month, on June 29, 2026, Larimar released further updates from their clinical study while also confirming the progress in their application process for the drug. They submitted the first section of the rolling Biologics License Application (BLA) to seek accelerated approval for nomlabofusp. However, similar to the previous announcement, this report also raised flags concerning ongoing safety signals, with anaphylaxis incidents reported among an increased number of patients. Specifically, this time, 10 out of 43 patients dealt with severe allergic reactions, leading to another stock price drop of 12.57%, ultimately bringing shares down to $3.20.

Given these developments, it's crucial for affected investors to understand their rights and possible recourse. Pomerantz encourages anyone impacted to reach out and share their experiences, potentially becoming part of a class action. Interested parties can contact Danielle Peyton directly via email at [email protected] or by phone at 646-581-9980, extension 7980.

Pomerantz LLP is a highly respected firm known for its commitment to fighting for investors' rights. With over 85 years of experience in securities class actions, they have successfully represented victims of corporate misconduct, recovering notable damages for their clients. Investors and stakeholders in Larimar Therapeutics should be vigilant and informed about their options as the investigation unfolds, given the potential implications for the company's future and investors' financial security.

For more information regarding the investigation and to participate in any upcoming collective efforts, stakeholders are encouraged to visit Pomerantz's official website at www.pomlaw.com.

As the landscape around Larimar Therapeutics continues to evolve, both current and potential investors must stay informed and proactive in protecting their interests in what could be a pivotal moment for this biotech firm. Thorough understanding and timely responses to these legal inquiries will be essential in navigating the upcoming challenges and opportunities presented by the ongoing developments in clinical research and corporate governance at Larimar.